Herpes zoster in SLE: prevalence, incidence and risk factors

Andrew Kwan,[1] Hanan Al Rayes,[2] Tijana Lazova,[3] Nicole Anderson,[4] Dennisse Bonilla,[4] Jiandong Su,[4] Zahi Touma [1,5]

[1]Department of Medicine, University of Toronto, Toronto, Ontario, Canada
[2]Department of Medicine, Prince Sultan Military Medical City, Riyadh, Riyadh, Saudi Arabia
[3]Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
[4]Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada
[5]Department of Medicine, Division of Rheumatology, University Health Network, Toronto, Ontario, Canada

Correspondence to
Dr Zahi Touma; Zahi.Touma@uhn.ca

ABSTRACT

Objectives This study aimed to evaluate the prevalence and incidence of herpes zoster (HZ) events and describe its associated factors in a study of patients with SLE.

Methods 491 consecutive SLE participants were screened for HZ events using a patient-reported questionnaire to capture outcomes on pain and other characteristics associated with HZ events. Sociodemographic, clinical and laboratory measures were also analysed, and time-dependent Cox regression survival analyses were performed to investigate factors associated with HZ events.

Results Prevalence of HZ was 30.5%, incidence was 14.3 cases per 1000 person-years. Lymphopenia and glucocorticoid dosing were significantly associated with HZ events.

Conclusions HZ is highly prevalent in SLE, which may be linked to disease-related and treatment-related effects on cellular immunity. Our results suggest that the presence of certain risk factors may be useful to allow identification of patients at risk of HZ and improve its management in patients with SLE.

Key messages

What is already known about this subject?
► Higher prevalence and incidence of herpes zoster (HZ) events are present in patients with SLE compared with the general population—thought to be a result of differences in cell-mediated immunity. Certain risk factors have been identified in the literature, including disease activity and immunosuppressive therapies, though findings have been inconsistent.

What does this study add?
► This study assesses the prevalence and incidence of HZ events in a lupus cohort using data from a novel questionnaire developed to assess patient-reported outcomes on characteristics related to HZ events, including pain, vaccination status, hospitalisations, treatments, complications of HZ events and onset after SLE diagnosis.
► A significant association exists between the development of HZ events in patients with SLE and lymphopenia, as well as glucocorticoid dosing.

How might this impact on clinical practice or future developments?
► The identification of associated factors from this study will allow targeted screening of patients at higher risk to allow for earlier diagnosis and improved management of HZ events in patients with SLE.
► Furthermore, risk factors identified give insight into the pathophysiology behind opportunistic infections in SLE and may allow improved treatment modalities, as well as a more complete understanding of HZ events in patients with SLE.

INTRODUCTION

Herpes zoster (HZ) is caused by the reactivation of latent varicella-zoster virus (VZV) in patients that may have experienced an exposure up to decades prior.[1] The infection can manifest as an acute painful vesicular rash that presents in a dermatomal pattern and can be followed by a persistent postzoster pain (postherpetic neuralgia).[1] HZ and the occurrence of postzoster pain have also been shown to have significant impacts on healthcare costs,[2 3] loss of productivity[4 5] and patients' health-related quality of life.[6 7]

Recurrent infection is most commonly seen in elderly and immunocompromised populations—including patients with malignancies,[8 9] acquired immune deficiency syndrome, autoimmune diseases such as rheumatoid arthritis[9–12] and SLE).[9 13 14] In the general population, HZ incidence ranges between 1.2 and 4.9 cases per 1000 person-years.[15 16] In comparison, the incidence is increased sixfold in SLE, where the incidence ranges from 6.4 to 37.7 cases per 1000 person-years.[13 14] Across all age groups in SLE, an age-adjusted HZ incidence rate has been shown to be 12 cases per 1000 patient-years.[1]

HZ incidence has been attributed to declining VZV-specific cell-mediated immunity.[17] As a result, it would also explain the increased incidence in SLE, where patients have been shown to have abnormal T cell mediated cytotoxicity and suppression of cellular immunity from both disease activity and immunosuppressive therapies, including glucocorticoids.[18] Other risk factors for

developing HZ in patients with SLE have been studied, though findings have been inconsistent.[19–21] In this study, we aimed to evaluate the prevalence and incidence of HZ, and describe its associated factors in a study of patients with SLE. We also determined patient-reported outcomes on pain and other characteristics related to HZ events based on a questionnaire developed for this study.

METHODS
Study design and patient selection
In this prospective cross-sectional study, a patient-reported questionnaire was developed by the Toronto Lupus Clinic (figure 1) to investigate HZ events in patients with SLE, capturing items related to patients' demographics, HZ symptoms, onset, recurrence, vaccinations or hospitalisations related to HZ, and other factors associated with HZ events. This questionnaire was distributed to patients visiting the clinic between May 2016 to November 2018. All patients fulfilled ≥4 of the American College of Rheumatology (ACR) revised criteria for the classification of SLE, or 3 ACR criteria and a typical biopsy lesion of SLE.[22] All patients provided informed written consent for participation in this study.

Patient assessment
SLE Disease Activity Index 2000 (SLEDAI-2K, SLEDAI-2K glucocorticoid index (SLEDAI-2KG), and the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) were determined for each patient.[23–25] The clinical variables evaluated in this study were SLEDAI-2K scores at each visit, SDI scores at each visit, presence of fibromyalgia within the past 6 months and SLEDAI-2K manifestations at each study visit.[24 25] SLE clinical phenotypes were stratified based on the nine organ systems of SLEDAI-2K, including skin (skin rash, alopecia and mucosal ulcers), central nervous system (seizure, psychosis, organic brain syndrome, cranial nerve involvement, visual disturbance, lupus headache, cerebrovascular accident and vasculitis), musculoskeletal (MSK) (arthritis and myositis), renal (proteinuria, hematuria, pyuria and urinary casts), serosal (pleuritis and pericarditis), haematological (leucopenia and thrombocytopenia), immunological (low complements and positive anti-dsDNA antibodies), and constitutional (fever) symptoms.[25] Other variables included age, gender, ethnicity, demographic characteristics such as disease duration, age at SLE diagnosis, SLE disease duration at first HZ event and recurrent HZ events.

Statistical methodology
Description of cohort and HZ events
Patients were classified based on the presence of HZ symptoms over the duration of the study. Demographic, clinical and laboratory data for patients with and without HZ events, at their first visit to clinic, were described using mean±SD and count (percentage) to represent continuous and categorical variables, respectively. The incidence rates for the first and all HZ events were calculated using follow-up person-years from the patients' first clinic visit to the date of survey completion. The CI of the incidence rate was estimated based on the assumption that the number of events occurring in a fixed interval of time follow a Poisson distribution. A Kaplan-Meier curve was created for the cumulative probability to first HZ event with 95% CIs and number of patients at risk over time.

Association between demographics, clinical and laboratory variables with HZ events
Three time-dependent survival analyses were performed to investigate factors associated with first or recurrent HZ events. The same variables were included in all three models: the first model with SLEDAI-2K, the second model with SLEDAI-2KG and a third model focused on studying the association with nine organ systems based on SLEDAI-2K. SLEDAI-2K and SLEDAI-2KG were completed at each clinical visit including the visit of the questionnaire fulfilment, while the SDI was performed annually. Counting process survival data were constructed for the three time-dependent Cox regressions (for the first event and repeated events). This was calculated from the date of first visit to the date of the first HZ event, or until the most recent visit for which the patient remained HZ-free. Explanatory variables in the models were included based on clinical relevance and literature review. Variables with potential collinearities were not included into the same regression model; these included the individual SLEDAI-2K organ systems, as well as SLEDAI-2K scores and glucocorticoid dosing in the SLEDAI-2KG model. A stepdown variable selection method was used in the multivariable model-building process; variables with highest p values were selected out using the Akaike Information Criterion as the model fitting statistic. The collinearities between total SLEDAI-2K Score and three relevant laboratory tests, including leucopenia, neutropenia and lymphopenia were assessed and demonstrated low correlations. As a result, the positive or negative laboratory results were entered into the three multivariable regressions as binary covariates.

The counting process model for recurrent data in survival analysis was used, where each HZ event was assumed to be independent and the subject contributes to the risk set if the subject was under observation at the time the event occurred.[26] All analyses were performed in SAS V.9.3 with statistical significance deemed to be under 0.05.

RESULTS
Cohort characteristics
Over the duration of the study, from May 2016 to November 2018, there were a total of 956 patients that attended the Toronto Lupus Clinic; each of them was approached to participate in the study. Of those, 491 patients completed the study questionnaire, 2 of which did not complete the first question '*Have you ever had painful vesicular skin rash (shingles=herpes zoster virus) as shown in this picture*' and

Shingles Survey

Study ID: _____   Date (dd/mm/yyyy)_____/_____/_____

1. Have you ever had painful vesicular skin rash (shingles = herpes zoster virus) as shown in this picture?

The rash is usually on one side of the body with a distribution similar to the areas in the picture

Yes ☐   If yes, what was the date of your first infection (year/month): _____

No ☐

2. Have you had a recurrent shingles infection?

Yes ☐   If yes, what was the date(s) of your infection(s) (year/month): _____

No ☐   _____

3. If you developed shingles after being diagnosed with lupus, when did it occur (first time)?

☐ 1-5 years post lupus diagnosis

☐ 6-10 years post lupus diagnosis

☐ More than 10 years post lupus diagnosis

4. Did you develop pain, itching or tingling in the rash area?

Yes ☐   If yes, how severe was the pain? Circle the appropriate number

No ☐

No pain   0—1—2—3—4—5—6—7—8—9—10   Severe pain

5. Was the diagnosis of shingles confirmed by a physician?

Yes ☐

No ☐

Shingles Survey

Study ID: _____   Date (dd/mm/yyyy)_____/_____/_____

6. Have you ever received varicella zoster vaccine?

Yes ☐

No ☐

7. Did you require hospitalization for severe shingles?

Yes ☐

No ☐

8. Did you receive treatment (e.g. anti-viral) for shingles?

Yes ☐

No ☐

9. Did you develop severe pain after the shingles infection?

Yes ☐   If yes, how long did your pain last?   3 Months ☐

No ☐   3-6 Months ☐

                                                        More than 6 months ☐

10. What lupus treatment was used at the time of your shingles infection? Check all that apply

☐ **Prednisone   If taken, what was the dose in mg/day?** _____

☐ **Plaquenil (Hydroxychloroquine)**

☐ **Imuran (Azathioprine)**

☐ **Cellcept (Mycophenolate Mofetil) or Myfortic**

☐ **Cyclophosphamide**

☐ **Belimumab (Benlysta)**

☐ **Rituximab**

☐ **Methotrexate**

☐ **Other treatment   If taken, specify:** _____

Figure 1   Herpes zoster (HZ) survey.

were excluded from the analysis. Of the 489 remaining patients, 149 reported having an HZ event and 340 never experienced an HZ event. Among the 149 patients with an HZ event, 26 did not report the year of the HZ event and were excluded from further analyses. Furthermore, 41 participants reported their HZ event prior to their first visit to the clinic—these patients were also excluded from the analyses. The final cohort therefore comprised of 422 patients with SLE.

In this cohort of 422 patients, the majority were female and Caucasian, followed by Black, Chinese and others. This was balanced across both the patients that reported HZ events and those that did not. The average ages at SLE diagnosis for patients with HZ and patients without HZ events were 29.3±12.0 years and 31.0±11.4 years, respectively. The mean age at the patient's first clinic visit was 33.4±12.8 years for patients reporting HZ events and 35.2±11.6 years for patients that did not report HZ. The mean SLE disease duration at the time of study was 4.2±6.4 years for both groups.

The prevalence of HZ in our cohort was 30.5% and the incidence was 14.0 cases per 1000 person-years (95% CI 11.5 to 17.7), with 82 reporting occurrence of HZ since following at the clinic, and 340 patients that did not develop HZ. Among the 82 patients with HZ, 16 reported recurrence of HZ within 8.7±10.4 years from the initial event; including these recurrent events, this resulted in an HZ incidence rate of 17.0 cases per 1000 person-years (95% CI 14.0 to 20.8).

MSK involvement was significantly higher among patients reporting HZ events, though this was not statistically significant after Bonferroni adjustment. No statistically significant differences were found in the prevalence of other SLEDAI-2K manifestations, including central nervous system (CNS), vascular, renal, skin, serosal, immunological, haematological or constitutional symptoms. Demographics of patients with SLE with and without HZ included in our study are presented in tables 1 and 2.

Description of HZ events
Among the 82 patients that reported HZ events, 35.4% reported HZ occurrence within the first 5 years of initial SLE diagnosis, 14.6% after 6–10 years of diagnosis and 50% occuring more than 10 years after SLE diagnosis. Mean SLE duration at first HZ event was 12.5±10.6 years. The majority of patients (98.8%) had their HZ event confirmed by a physician, with 80% receiving antiviral therapy and 15.9% requiring hospitalisation for severe HZ. Most patients (84.2%) who developed HZ never received a varicella zoster vaccine. HZ symptoms, involving rash with associated pain, itching or tingling, occurred in 95.1% of patients, with 74% rating the pain between 7 and 10 (figure 2). More than half (55.7%) of the patients experienced severe pain after HZ infection, lasting up to 3 months in duration in 48.8%, 3–6 months in 17.1%, and beyond 6 months in 34.2% of patients. There was no correlation between pain severity and 'time since HZ event', with a Spearman correlation coefficient

| | | | **No HZ** | **HZ event** | |
| **Table 1** | Demographic and clinical description of patients at fulfilment of the questionnaire, n=422 | | | | |
	Variable	Value	**No HZ** n=340	**HZ event** n=82	P value
Demographics	Sex	F	308 (90.6%)	78 (95.1%)	0.19
		M	32 (9.4%)	4 (4.9%)	
	Age at SLE diagnosis	Mean±SD	31.0±11.4	29.3±12.0	0.22
		Min, Max	8–66	8–76	
	Age at first visit to the clinic	Mean±SD	35.2±11.6	33.4±12.8	0.22
		Min, Max	16–68	14–76	
	SLE duration at first visit to the clinic	Mean±SD	4.2±6.4	4.2±6.4	0.94
		Min, Max	16–68	0–32	
	Ethnicity	Black	72 (21.2%)	8 (9.8%)	0.03
		Caucasian	196 (57.6%)	60 (73.2%)	
		Chinese	27 (7.9%)	8 (9.8%)	
		Others	45 (13.2%)	6 (7.3%)	
	Caucasian	Yes (%)	196 (57.6%)	60 (73.2%)	0.01
	Black	Yes (%)	72 (21.2%)	8 (9.8%)	0.02
	SLE duration at first HZ event	Mean±SD	N/A	12.5±10.6	N/A
HZ events	Age at first HZ event	Mean±SD	N/A	41.8±15.4	N/A
	Recurrent HZ infection	Yes (%)	N/A	16 (19.5%)	N/A
	Years between first and second HZ event	Mean±SD	N/A	8.7±10.4	N/A
	SDI score	Mean±SD	0.2±0.6	0.2±0.5	0.52

HZ, herpes zoster; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index .

Table 2 SLE clinical manifestations stratified by organ systems of SLEDAI-2K

Variable	Value	No HZ n=340	HZ event n=82	P value	Bonferroni adjusted
Central nervous system	Yes (%)	32 (9.4%)	9 (11.0%)	0.67	1.00
Vasculitis	Yes (%)	25 (7.4%)	8 (9.8%)	0.47	1.00
Musculoskeletal	Yes (%)	65 (19.1%)	24 (29.3%)	0.04	0.33
Renal	Yes (%)	78 (22.9%)	16 (19.5%)	0.50	1.00
Skin	Yes (%)	139 (40.9%)	41 (50.0%)	0.13	0.72
Serosal	Yes (%)	26 (7.6%)	7 (8.5%)	0.79	1.00
Immunological	Yes (%)	229 (67.4%)	51 (62.2%)	0.38	0.98
Constitutional	Yes (%)	30 (8.8%)	8 (9.8%)	0.79	1.00
Haematological	Yes (%)	36 (10.6%)	8 (9.8%)	0.83	1.00
SLEDAI-2K	Mean±SD	7.7±6.8	8.5±7.8	0.32	–
SLEDAI-2KG	Mean±SD	5.5±3.0	5.9±3.1	0.34	–

HZ, herpes zoster; SLEDAI-2K, SLE Disease Activity Index 2000; SLEDAI-2KG, SLEDAI-2K Glucocorticoid Index.

0.18 (p=0.16, n=65/82), suggesting that the time since HZ event had no significant impact on the recall of pain severity. Survival analyses showed that the cumulative risk of developing HZ increased with time after diagnosis of SLE (figure 3). Description of HZ events have been presented in table 3.

Fifty-nine patients (71.9%) reported being on prednisone for SLE at the time of the HZ event. Of those, 43 patients reported a mean prednisone dose of 22.3 mg/day (range, 1–60 mg/day) (table 3). Fourty-nine patients (59.4%) were on immunosuppressant therapy, including azathioprine (35%), mycophenolate mofetil (17.1%), methotrexate (4.9%) and cyclophosphamide (2.4%) (table 3).

Association between HZ events and patient characteristics, clinical and laboratory variables
No demographic characteristics, including gender, age at diagnosis, age at first visit or ethnicity were associated with development of HZ in either the univariable or the three multivariable models (table 4).

Model with SLEDAI-2K
Lymphopenia was associated with HZ events in the univariable analysis (HR=1.77; 95% CI 1.12 to 2.80; p=0.01) and in the multivariable analysis (HR=1.63; 95% CI 1.02 to 2.59; p=0.04). There was an association between HZ events and SLEDAI-2K Score, though only for the univariable analysis (HR=1.06; CI 1.02 to 1.11; p=0.004).

Figure 2 Herpes zoster pain severity as reported by patients with SLE (n=138). STD, standard deviation.

Figure 3 Kaplan-Meier cumulative risk for first herpes zoster event.

No association was found between SDI scores and HZ events in either the univariable or multivariable models (table 4).

Glucocorticoid dosing was associated with HZ events in the univariable (HR=1.02; 95% CI 1.01 to 1.02; p=*0.0001*) and multivariable analysis with SLEDAI-2K (HR=1.01; 95% CI 1.00 to 1.02; p=*0.03*).

Model with SLEDAI-2KG

In this model, lymphopenia did not sustain significance (HR=1.56; 95% CI 0.98 to 2.49; p=*0.06*). There was an association between HZ events and SLEDAI-2KG scores in both the univariable (HR=1.21; CI 1.1 to 1.33; p<*0.0001*) and multivariable analysis with SLEDAI-2KG (HR=1.18; CI 1.06 to 1.31; p=0.002) (table 4).

Model with SLEDAI-2K organ systems

In this model, the only variable that was associated with HZ events was lymphopenia (HR=1.64; 95% CI 1.03 to 2.60; p=*0.04*). Neither SLEDAI-2K organ scores or SDI scores were associated with HZ events. Furthermore, glucocorticoid dosing did not sustain significance (HR=1.01; 95% CI 1.00 to 1.02; p=*0.06*) (data not shown in table 3).

DISCUSSION

The prevalence and incidence of HZ in this study were 30.5% and 14.3 cases per 1000 person-years, respectively. This is in keeping with findings published in the literature of prevalence varying from 13.5% to 46.6% of adult patients with SLE,[27] and incidence in SLE ranging from 6.3 to 37.7 cases per 1000 person-years.[13 14] Furthermore, the HZ recurrence rate in our study was 1.7%. This is similar to results from a study by Yawn *et al*, where they demonstrated a recurrence rate of 1.4%, within 3 years, in a general population-based study of 1669 adult residents.[28] In SLE, it is recognised that HZ is a late complication—with one study showing two-thirds of patients with an SLE disease duration greater than 5 years.[13] In our study, the SLE disease duration at the time of the first HZ infection was 12.5±10.6 years.

From our questionnaire, most patients who developed HZ had not been vaccinated against varicella zoster, which may suggest a clinical gap that can be addressed to reduce susceptibility to HZ infections. However, while guidelines recommend live attenuated vaccines for prevention of HZ in healthy adults over 60 years of age, the use of live vaccines has been limited in SLE due

Table 3 Results of the HZ Questionnaire

Onset after SLE diagnosis	Frequency (%)
1–5 years post-SLE diagnosis	29 (35.4)
6–10 years post-SLE diagnosis	12 (14.6%)
>10 years post-SLE diagnosis	41 (50.0%)
HZ symptoms: occurrence of pain, itching, tingling with rash	
No	4 (4.9%)
Yes	78 (95.1%)
Confirmed of HZ diagnosis by physician	
No	1 (1.2%)
Yes	81 (98.8%)
Vaccination history: ever received varicella zoster vaccine	
No	69 (84.2%)
Yes	13 (15.9%)
Hospitalisations: ever hospitalised for severe HZ?	
No	69 (84.2%)
Yes	13 (15.9%)
Treatment for HZ : ever received treatments (eg, antivirals) for HZ?	
No	16 (20%)
Yes	64 (80%)
Missing	2
Postherpetic neuralgia: history of severe pain after HZ infection?	
No	35 (44.3%)
Yes	44 (55.7%)
Missing	3
Duration of postherpetic neuralgia, if present	
3 months	20 (48.8%)
3–6 months	7 (17.1%)
>6 months	14 (34.2%)
Missing	3
SLE treatments at time of HZ infection?	
Prednisone	59 (71.9%)
Hydroxychloroquine	50 (61%)
Azathioprine	29 (35%)
Mycophenolate mofetil or mycophenolic acid	14 (17.1%)
Cyclophosphamide	2 (2.4%)
Belimumab	0 (0%)
Rituximab	2 (2.4%)
Methotrexate	4 (4.9%)
Other treatment	15 (18.3%)

Prednisone dose in mg/day, if taken								
Frequency	Missing	Minimum dose	Mean dose	SD	Median dose	Lower quartile	Upper quartile	Maximum dose
23	36	1	22.3	19.5	15	5	30	60

HZ, herpes zoster.

to evidence of increased risk of severe adverse events in immunocompromised patients.[29–31] Newer recombinant zoster vaccines, such as the non-live Varicella zoster vaccine recombinant, adjuvanted, have shown utility in patients with SLE[32] and may provide an alternate option to circumvent the need for live HZ vaccines. This is in

Table 4 Time-dependent survival analyses using three regression models with SLEDAI-2K, SLEDAI-2KG and SLEDAI organ systems

		Univariable cox regression		Multivariable analysis with SLEDAI-2K		Multivariable analysis with SLEDAI-2KG	
		HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Demographics	Female sex	1.89 (0.69 to 5.17)	0.22	2.41 (0.76 to 7.67)	0.13	2.51 (0.79 to 7.98)	0.12
	Age at SLE diagnosis	1.00 (0.98 to 1.02)	0.77				
	Age at first visit	1.00 (0.98 to 1.02)	0.73				
	Caucasian	1.46 (0.89 to 2.38)	0.13			1.41 (0.85 to 2.32)	0.18
Study protocol	SLEDAI-2KG at each visit	1.21 (1.10 to 1.33)	<0.0001			1.178 (1.06 to 1.31)	0.002
	SLEDAI-2K at each visit	1.06 (1.02 to 1.11)	0.004	1.04 (0.99 to 1.09)	0.11		
	SDI score	0.87 (0.72 to 1.10)	0.14	0.84 (0.69 to 1.02)	0.10	0.84 (0.69 to 1.02)	0.09
	Fibromyalgia	0.94 (0.48 to 1.85)	0.86				
Treatment	Glucocorticoid Use	1.66 (1.04 to 2.66)	0.03			Not entered into multivariable analysis, part of SLEDAI-2KG	
	Glucocorticoid dose (mg/day)	1.02 (1.01 to 1.02)	0.0001	1.01 (1.001 to 1.02)	0.03		
	Antimalarial	1.19 (0.75 to 1.90)	0.46				
	Treated with Immunosuppressives	1.52 (0.98 to 2.36)	0.06				
Laboratory markers	Antiphospholipid antibody at any time	0.94 (0.48 to 1.85)	0.86				
	Leucopenia (WBC<4.0*10^9/L)	1.27 (0.51 to 3.2)	0.60				
	Neutropenia (<1.5* 10^9)	0.83 (0.40 to 1.73)	0.62				
	Lymphopenia (<1.0* 10^9)	1.78 (1.12 to 2.80)	0.01	1.63 (1.02 to 2.59)	0.041	1.56 (0.98 to 2.49)	0.06
	Anaemia	1.25 (0.78 to 2.02)	0.36				
	Low IgA	1.52 (0.21 to 10.10)	0.68				
	Low IgG	1.61 (0.39 to 6.58)	0.51				
	Low IgM	1.12 (0.35 to 3.55)	0.85				

*All of the above variables were time-dependent with the exception of: female sex, age at SLE diagnosis, age at first visit and Caucasian ethnicity.

*In the third multivariable regression model with SLEDAI organ systems, lymphopenia was the only statistically significant predictor of HZ events (HR=1.64, 95% CI 1.03 to 2.95, p=0.037), the other adjusted variables in the model included SLEDDAI-2K organ systems, SDI and glucocorticoid dose which did not sustain significance. As a result this was not included in the above table.

HZ, herpes zoster; SLEDAI-2K, SLEDAI-2K, SLE Disease Activity Index 2000; SLEDAI-2KG, SLEDAI-2K Glucocorticoid Index; WBC, white blood cells.

keeping with the 2019 EULAR guidelines for vaccinations in patients with autoimmune inflammatory rheumatic diseases, including SLE. Large retrospective studies have shown the effectiveness of the HZ vaccine in reducing incidence of HZ over a 2-year follow-up period, regardless of medication use, offering protection for approximately 5 years in those with autoimmune diseases.[33]

Postherpetic neuralgia is the most common complication of HZ, and in our study, 34% of patients developed severe pain lasting beyond 90 days of their initial HZ infection. This prevalence is similar to what is reported in the literature for the general population, with studies reporting 22%–48% of adult patients reporting symptoms of postherpetic neuralgia.[28 34–36] Overall, less than 20% required hospitalisation for severe HZ, which is also in keeping with other studies.[13]

Over half of our patients who developed HZ were on immunosuppressant therapy, with 72% of patients on glucocorticoids at the time of the HZ event, and a mean dose of 22.3 mg/day. Our analyses confirmed the association of glucocorticoid dosing with HZ events, a finding that is in keeping with similar studies that have shown immunosuppressive therapies to be risk factors for development of HZ infections in patients with SLE.[8 12 14 37–40] This is thought to be mediated through effects on inhibiting T-lymphocyte-mediated and B-lymphocyte-mediated immune responses, as well as their suppressive effects on monocytes and neutrophils.[41 42] In one study by Shah et al, a mean daily dose greater than 7.5 mg of prednisone resulted in increased susceptibility of opportunistic infection such as HZ, pneumonia and other fungal infections;[43] with evidence of a strong dose-response relationship for glucocorticoids.[39] It is worth noting that glucocorticoid dosing may also be an indication of the level of SLE disease activity, which in itself may be a risk factor for HZ events—independent of immunosuppressive therapy.[44] Another factor associated with HZ events across both univariable and multivariable regression analyses included lymphopenia—which has been shown in literature to be an independent risk factor for HZ in patients with SLE[20 45–48] and may be a result of both lupus-related and treatment-related effects on lymphocyte-mediated immune responses. Both Ng et al and Hu et al showed that frequency of lymphopenia was higher in patients with SLE that developed HZ. The exact mechanism of this is not well understood, and it is hypothesised that this may be a result of defective cell-mediated immunity, an integral component of defence against VZV reactivation.[45 49 50]

In our univariable and multivariable analyses, we found an association between SLEDAI-2KG scores and development of HZ. The literature surrounding the association between HZ events and disease activity is mixed, with some studies showing that the majority of zoster reactivation occurs during mild or inactive disease;[37 49 51] for example, in a study by Borba et al, nearly half of their patients with HZ reactivation had a SLEDAI score of 0—with most patients (82.4%) exhibiting a SLEDAI <8 (13). Contrary to this, other studies have demonstrated HZ association with higher disease activity.[20 52] In this study, association of HZ events with SLEDAI-2KG scores is likely due to the accounting of glucocorticoid dosing, a factor that is independently associated with HZ events. This hypothesis is supported by the fact that SLEDAI-2K scores, that do not account for glucocorticoid dosing, were not associated with HZ events in our multivariable analysis.

Possible limitations of this study include that only half of the approached patients agreed to participate in the study. Although further data were not collected around reasons for declining participation, this was most often related to patients' limited time and commitment to other activities after their clinic visit. While this may possibly introduce a selection bias resulting in an overestimation of prevalence, our results are consistent with those found in literature. Furthermore, HZ events were patient-reported and physician-confirmed. As we do not have details surrounding the method of confirmation, this may contribute to possible bias which could also affect the estimation of HZ prevalence and incidence. However, studies have shown that the accuracy of self-reported HZ can be quite reliable, which helps to mitigate this risk.[53] As we did not have a control group in this study, further studies will have to be performed to validate these findings in other SLE cohorts and to compare them with an immunocompetent group to determine their generalisability and possible use for predicting patients at high risk for HZ reactivation.

CONCLUSION

In conclusion, this study highlights the prevalence of HZ in an SLE patient cohort, while investigating the relationships among sociodemographic, clinical and laboratory variables. Measures such as lymphopenia and glucocorticoid dosing were associated with HZ development and are consistent with results of other reports suggesting an increased risk for HZ development in SLE that may be linked to both disease-specific immunological imbalances, as well as treatment regimens. Together, these risk factors may serve as useful indicators to be considered in patients with SLE to allow for closer monitoring for earlier diagnosis and improved management of HZ.

ORCID iD
Zahi Touma http://orcid.org/0000-0001-5177-2076

REFERENCES

1 Chakravarty EF, Michaud K, Katz R, *et al*. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. *Lupus* 2013;22:238–44.
2 Dworkin RH, White R, O'Connor AB, *et al*. Health care expenditure burden of persisting herpes zoster pain. *Pain Medicine* 2008;9:348–53.
3 White RR, Lenhart G, Singhal PK, *et al*. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. *Pharmacoeconomics* 2009;27:781–92.
4 Drolet M, Levin MJ, Schmader KE, *et al*. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. *Vaccine* 2012;30:2047–50.
5 Singhal PK, Makin C, Pellissier J, *et al*. Work and productivity loss related to herpes zoster. *J Med Econ* 2011;14:639–45.
6 Katz J, Cooper EM, Walther RR, *et al*. Acute pain in herpes zoster and its impact on health-related quality of life. *Clin Infect Dis* 2004;39:342–8.
7 Schmader KE, Sloane R, Pieper C, *et al*. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. *Clin J Pain* 2007;23:490–6.
8 Habel LA, Ray GT, Silverberg MJ, *et al*. The epidemiology of herpes zoster in patients with newly diagnosed cancer. *Cancer Epidemiol Biomarkers Prev* 2013;22:82–90.
9 Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. *Infection* 2011;39:537–44.
10 McDonald JR, Zeringue AL, Caplan L, *et al*. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. *Clin Infect Dis* 2009;48:1364–71.
11 Smitten AL, Choi HK, Hochberg MC, *et al*. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. *Arthritis Rheum* 2007;57:1431–8.
12 Strangfeld A *et al*. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. *JAMA* 2009;301:737–44.
13 Borba EF, Ribeiro ACM, Martin P, *et al*. Incidence, risk factors, and outcome of herpes zoster in systemic lupus erythematosus. *J Clin Rheumatol* 2010;16:119–22.
14 Chen H-H, Chen Y-M, Chen T-J, *et al*. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. *Clinics* 2011;66:1177–82.
15 Jih J-S, Chen Y-J, Lin M-W, *et al*. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. *Acta Derm Venereol* 2009;89:612–6.
16 Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? *Lancet Infect Dis* 2004;4:26–33.
17 Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. *Curr Opin Immunol* 2012;24:494–500.
18 Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. *Curr Opin Rheumatol* 2003;15:528–34.
19 Hu SC-S, Lin C-L, Lu Y-W, SC H, YW L, *et al*. Lymphopaenia, anti-Ro/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus. *Acta Derm Venereol* 2013;93:314–8.
20 Lee PPW, Lee T-L, Ho MH-K, *et al*. Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors. *Pediatr Infect Dis J* 2006;25:728–32.
21 Wu S-A, Yeh K-W, Yao T-C, *et al*. Association of herpes zoster infection with clinical characteristics and MBL2 gene polymorphisms in Chinese children with systemic lupus erythematosus. *Pediatr Infect Dis J* 2011;30:656–60.
22 Tan EM, Cohen AS, Fries JF, *et al*. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271–7.
23 Brunner HI, Silverman ED, Bombardier C, *et al*. European consensus lupus activity measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. *Arthritis Rheum* 2003;49:335–41.
24 Gladman D, Ginzler E, Goldsmith C, *et al*. The development and initial validation of the systemic lupus international collaborating clinics/American College of rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum* 1996;39:363–9.
25 Touma Z, Urowitz MB, Ibañez D, *et al*. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. *Lupus* 2011;20:67–70.
26 Hosmer DWL S, May S. *Applied survival analysis: regression modeling of Time-to-Event data*. 2nd edn. Wiley, 2008.
27 Sayeeda A, Al Arfaj H, Khalil N. Herpes zoster infections in SLE in a university hospital in Saudi Arabia: risk factors and outcomes. *Autoimmune Dis* 2011;2010:174891.
28 Yawn BP, Saddier P, Wollan PC, *et al*. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. *Mayo Clin Proc* 2007;82:1341–9.
29 Millet A, Decaux O, Perlat A, *et al*. Systemic lupus erythematosus and vaccination. *Eur J Intern Med* 2009;20:236–41.
30 Abu-Shakra M. Safety of vaccination of patients with systemic lupus erythematosus. *Lupus* 2009;18:1205–8.
31 Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. *J Infect Dis* 2008;197 Suppl 2:S237–41.
32 Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: the current status. *Hum Vaccin Immunother* 2019;15:45–8.
33 Furer V, Rondaan C, Heijstek MW, *et al*. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis* 2020;79:39–52.
34 Chen S-Y, Suaya JA, Li Q, *et al*. Incidence of herpes zoster in patients with altered immune function. *Infection* 2014;42:325–34.
35 Scott FT, Leedham-Green ME, Barrett-Muir WY, *et al*. A study of shingles and the development of postherpetic neuralgia in East London. *J Med Virol* 2003;70 Suppl 1:S24–30.
36 Kost RG, Straus SE. Postherpetic neuralgia — pathogenesis, treatment, and prevention. *N Engl J Med Overseas Ed* 1996;335:32–42.
37 Manzi S, Kuller LH, Kutzer J, *et al*. Herpes zoster in systemic lupus erythematosus. *J Rheumatol* 1995;22:1254–8.
38 Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. *Lupus* 2013;22:1286-94.
39 Hu SC-S, Yen F-L, Wang T-N, *et al*. Immunosuppressive medication use and risk of herpes zoster (Hz) in patients with systemic lupus erythematosus (SLE): a nationwide case-control study. *J Am Acad Dermatol* 2016;75:49–58.
40 Zhang J, Xie F, Delzell E, *et al*. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. *JAMA* 2012;308:43–9.
41 Luijten RKMAC, Cuppen BVJ, Bijlsma JWJ, *et al*. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. *Lupus* 2014;23:1512–6.
42 Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, *et al*. Predictors of major infections in systemic lupus erythematosus. *Arthritis Res Ther* 2009;11:R109.
43 Shah M, Chaudhari S, McLaughlin TP, *et al*. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. *Clin Ther* 2013;35:486–97.
44 Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. *J Rheumatol* 1991;18:1180–4.
45 Chen D, Li H, Xie J, *et al*. Herpes zoster in patients with systemic lupus erythematosus: clinical features, complications and risk factors. *Exp Ther Med* 2017;14:6222–8.
46 Ng WL, Chu CM, Wu AKL, *et al*. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. *QJM* 2006;99:37–47.
47 Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. *Arthritis Rheum* 1996;39:1475–82.

48 Ferreira JCOA, Marques HH, Ferriani MPL, *et al*. Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: a large multicenter study. *Lupus* 2016;25:754–9.

49 Nagasawa K, Yamauchi Y, Tada Y, *et al*. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. *Ann Rheum Dis* 1990;49:630–3.

50 Park H-B, Kim K-C, Park J-H, *et al*. Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. *J Rheumatol* 2004;31:2151–5.

51 Kahl LE. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. *J Rheumatol* 1994;21:84–6.

52 Gladman DD, Hussain F, Ibañez D, *et al*. The nature and outcome of infection in systemic lupus erythematosus. *Lupus* 2002;11:234–9.

53 Schmader K, George LK, Newton R, *et al*. The accuracy of self-report of herpes zoster. *J Clin Epidemiol* 1994;47:1271–6.